AlphAIAlphAI — Financial news for AI agents
investing.com$DCTH

Delcath Systems earnings beat by $0.26, revenue topped estimates

Delcath Systems (DCTH) reported Q3 EPS of $0.17, beating estimates by $0.26, with revenue of $35.1M, exceeding expectations of $26M. The company expects FY 2026 revenue of $115M-$117M, higher than the consensus of $106.2M. DCTH's stock is down 14% in the last 3 months but up 74% in the last 12 months.

Original reporting
investing.com
Published Nov 9, 2026, 1:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 1:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$DCTH
Bullish
high confidence
Mentioned
$DCTH
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$DCTHBullishMed
01

Why it matters

The earnings surprise and raised guidance could attract short‑covering and new buying.

02

Market read

Micro‑cap earnings beat with guidance lift provides a short‑term trading catalyst.

03

What to watch

Potential execution risk on the new revenue targets.

Relevance 7/10Novelty 7/10Timing: today

Background

Delcath Systems is a Nasdaq‑listed developer of hepatic drug delivery technologies.

Company-level read

Ticker impact

$DCTHBullishHigh confidence
Context

Delcath Systems reported Q3 EPS of $0.170 beating estimates by $0.26 and raised FY2026 revenue guidance to $115M-$117M.

Expected impact

likely upward pressure as investors price in the beat and higher guidance

Evidence & confidence

The surprise EPS beat and above‑consensus revenue outlook are fresh, material information for a micro‑cap stock.

Market effects

Sector

Improves outlook for the interventional oncology device sector.

Regional

Limited to U.S. small‑cap biotech space.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The beat may be priced in quickly, limiting upside.

Key entities

  • company
    Delcath Systems

    NASDAQ‑listed medical device firm.

Read at source← All news

StoryDelcath Systems posts Q3 2026 results, lifts full‑year revenue guidance

Also covered by

3 outlets

Related articles

$DCTHHighAI 8/10

Delcath Systems Inc (DCTH) (Q3 2026) Earnings Call Highlights: Record Revenue, Raised

Delcath Systems (DCTH) reported Q3 2026 revenue of $35.1M, up 71% YoY, driven by HEPZATO KIT sales. CEO Gerard Michel cited therapy adoption, physician demand, and expanded capacity as growth drivers. The company raised full-year revenue guidance to $115M-$117M. Q4 guidance implies a step-down due to holiday impact, with new patient starts expected to slow. The Phase II colorectal cancer trial interim analysis is now expected in Q2 or Q3 2027.

finance.yahoo.com
$EDSAMedAI 8/10

Healthcare Stocks Rally: EDSA And DCTH Jump 30%, VIR And IMVT Also Gain

Edesa Biotech (EDSA) and Delcath Systems (DCTH) shares rose 30% after signing a licensing deal and reporting strong Q3 results, respectively. Immunovant (IMVT) and Vir Biotechnology (VIR) shares gained 13% and 14% following positive clinical trial data. EDSA received $12M upfront, DCTH raised FY26 revenue outlook, IMVT met primary endpoint, and VIR showed undetectable HDV RNA in 28 patients.

rttnews.com
$DCTHMed

Delcath (DCTH) Q3 2026 Earnings Call Transcript

Delcath (DCTH) reported Q3 2026 revenue of $35.1M, up 71% YoY, driven by HEPZATO KIT adoption. The company added new treatment centers, including AdventHealth, and expects 36 centers by year-end. Clinical trials are progressing, with a Phase II colorectal trial on track for interim analysis in mid-2027. Full-year revenue guidance was raised to $115M-$117M, with Q4 expected to grow 25%-34% YoY.

finance.yahoo.com
$DCTHMed

Delcath Systems Reports 70% Revenue Growth in Q3 2026 and Raises Full-Year Guidance to $115 Million–$117 Million

Delcath Systems (DCTH) reported Q3 2026 revenue of $35.1M, up 70% YoY, driven by higher sales of its liver cancer treatment products. The company raised its full-year revenue guidance to $115M–$117M. Net income increased to $7.0M, and gross margin improved to 89%. HEPZATO KIT revenue grew 69% to $32.7M, while European CHEMOSAT revenue rose to $2.4M. Adjusted EBITDA increased to $11.5M, and operating cash flow reached $8.2M. Delcath also advanced its clinical development programs.

finance.yahoo.com
$DCTHMed

Delcath Systems Q3 Earnings Call Highlights

Delcath Systems (DCTH) raised its 2026 revenue guidance to $115M-$117M, projecting HEPZATO KIT volume growth of at least 41% over 2025. Q4 revenue is expected to be $25.8M-$27.8M, down sequentially but up 25%-34% year-over-year, due to holiday scheduling. Growth is attributed to increased use of HEPZATO, patient awareness, and expanded capacity at centers like MD Anderson and Mass General.

finance.yahoo.com